Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT00045786 | Study to Determine the Safety and Preliminary Efficacy of CC-1088 in the Treatment of Myelodysplastic Syndromes | PHASE2 | COMPLETED | 18 | — | — | Oct 1, 2001 | Nov 1, 2003 | Apr 25, 2017 | 1 | United States |
| Arm | Type | Description |
|---|---|---|
| 400 mg CC-1088 | EXPERIMENTAL | - |
| 800 mg CC-1088 | EXPERIMENTAL | - |
| 1200 mg CC-1088 | EXPERIMENTAL | - |
| 1500 mg CC-1088 | EXPERIMENTAL | - |
| Name | Type | Description |
|---|---|---|
| CC-1088 | DRUG | 400 mg/day (200 mg orally twice a day) 800 mg/day (400 mg orally twice a day) 1200 mg/day (600 mg orally twice a day) 1500 mg/day (500 mg orally three times daily) |
Inclusion Criteria: * Eligible patients must have a diagnosis of MDS of at least 12 weeks that is not therapy related. * Age ≥ 18 at the time of signing informed consent * Patient must be able to adhere to the study visit schedule and other protocol requirements. * Patient must understand and volun...